Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*
Jan Bakker(Intensive Care Society), Jukka Takala(University of Bern), Steven H. Grossman(GlaxoSmithKline (Netherlands)), Jill Donaldson(GlaxoSmithKline (Netherlands)), Jan Andersson, Angela McLuckie(Guy's Hospital), Laurent Holzapfel(Servier (France)), David I. Watson(Flinders University), Robert F. Grover(GlaxoSmithKline (Netherlands)), Robert F. Lodato
Cited by 196
Related Papers
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.6k
Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units
|Critical Care Medicine|1998|3.5k
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*
|Critical Care Medicine|2004|921
Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score
|Intensive Care Medicine|2000|740
A Prospective, Randomized Study of Goal-Oriented Hemodynamic Therapy in Cardiac Surgical Patients
|Anesthesia & Analgesia|2000|564